[1]
|
Agrawal, V., Benjamin, K.T. and Ko, E.C. (2020) Radiotherapy and Immunotherapy Combinations for Lung Cancer. Current Oncology Reports, 23, Article No. 4. https://doi.org/10.1007/s11912-020-00993-w
|
[2]
|
Curran, W.J., Paulus, R., Langer, C.J., Komaki, R., Lee, J.S., Hauser, S., et al. (2011) Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. JNCI Journal of the National Cancer Institute, 103, 1452-1460. https://doi.org/10.1093/jnci/djr325
|
[3]
|
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W.J., Furuse, K., Fournel, P., et al. (2010) Meta-Analysis of Concomitant versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 28, 2181-2190. https://doi.org/10.1200/jco.2009.26.2543
|
[4]
|
Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 379, 2342-2350. https://doi.org/10.1056/nejmoa1809697
|
[5]
|
Dams, R.V., Yuan, Y., Robinson, C.G. and Lee, P. (2020) Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer—A Stimulating Partnership. Seminars in Respiratory and Critical Care Medicine, 41, 360-368. https://doi.org/10.1055/s-0039-3399578
|
[6]
|
Zhang, Y., Huang, C. and Li, S. (2023) Influence of Treatment-Related Lymphopenia on the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer: A Meta-Analysis. Frontiers in Oncology, 13, Article 1287555. https://doi.org/10.3389/fonc.2023.1287555
|
[7]
|
Kang, J., Zhang, C. and Zhong, W. (2021) Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer: State of the Art. Cancer Communications, 41, 287-302. https://doi.org/10.1002/cac2.12153
|
[8]
|
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R.R., et al. (2014) Irradiation and Anti-PD-L1 Treatment Synergistically Promote Antitumor Immunity in Mice. Journal of Clinical Investigation, 124, 687-695. https://doi.org/10.1172/jci67313
|
[9]
|
Bassanelli, M., Ricciuti, B., Giannarelli, D., Cecere, F.L., Roberto, M., Giacinti, S., et al. (2021) Systemic Effect of Radiotherapy before or after Nivolumab in Lung Cancer: An Observational, Retrospective, Multicenter Study. Tumori Journal, 108, 250-257. https://doi.org/10.1177/03008916211004733
|
[10]
|
Theelen, W.S., de Jong, M.C. and Baas, P. (2020) Synergizing Systemic Responses by Combining Immunotherapy with Radiotherapy in Metastatic Non-Small Cell Lung Cancer: The Potential of the Abscopal Effect. Lung Cancer, 142, 106-113. https://doi.org/10.1016/j.lungcan.2020.02.015
|
[11]
|
Formenti, S.C., Rudqvist, N., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., et al. (2018) Radiotherapy Induces Responses of Lung Cancer to CTLA-4 Blockade. Nature Medicine, 24, 1845-1851. https://doi.org/10.1038/s41591-018-0232-2
|
[12]
|
Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H. and Yu, J. (2018) Abscopal Effect of Radiotherapy Combined with Immune Checkpoint Inhibitors. Journal of Hematology & Oncology, 11, Article No. 104. https://doi.org/10.1186/s13045-018-0647-8
|
[13]
|
Beasley, M.B., Brambilla, E. and Travis, W.D. (2005) The 2004 World Health Organization Classification of Lung Tumors. Seminars in Roentgenology, 40, 90-97. https://doi.org/10.1053/j.ro.2005.01.001
|
[14]
|
Souquet, P.J. and Geriniere, L. (2001) The Role of Chemotherapy in Early Stage of Non-Small Cell Lung Cancer. Lung Cancer, 34, S155-S158. https://doi.org/10.1016/s0169-5002(01)00361-0
|
[15]
|
Robinson, C.G., DeWees, T.A., El Naqa, I.M., Creach, K.M., Olsen, J.R., Crabtree, T.D., et al. (2013) Patterns of Failure after Stereotactic Body Radiation Therapy or Lobar Resection for Clinical Stage I Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 8, 192-201. https://doi.org/10.1097/JTO.0b013e31827ce361
|
[16]
|
Altorki, N.K., McGraw, T.E., Borczuk, A.C., Saxena, A., Port, J.L., Stiles, B.M., et al. (2021) Neoadjuvant Durvalumab with or without Stereotactic Body Radiotherapy in Patients with Early-Stage Non-Small-Cell Lung Cancer: A Single-Centre, Randomised Phase 2 Trial. The Lancet Oncology, 22, 824-835. https://doi.org/10.1016/s1470-2045(21)00149-2
|
[17]
|
Tian, S., Switchenko, J.M., Buchwald, Z.S., Patel, P.R., Shelton, J.W., Kahn, S.E., et al. (2020) Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. International Journal of Radiation Oncology∙Biology∙Physics, 108, 304-313. https://doi.org/10.1016/j.ijrobp.2019.12.030
|
[18]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375, 1823-1833. https://doi.org/10.1056/nejmoa1606774
|
[19]
|
Verma, V., Shostrom, V.K., Zhen, W., Zhang, M., Braunstein, S.E., Holland, J., et al. (2017) Influence of Fractionation Scheme and Tumor Location on Toxicities after Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-Institutional Analysis. International Journal of Radiation Oncology∙Biology∙Physics, 97, 778-785. https://doi.org/10.1016/j.ijrobp.2016.11.049
|
[20]
|
Verma, V., Shostrom, V.K., Kumar, S.S., Zhen, W., Hallemeier, C.L., Braunstein, S.E., et al. (2016) Multi-Institutional Experience of Stereotactic Body Radiotherapy for Large (≥5 Centimeters) Non-Small Cell Lung Tumors. Cancer, 123, 688-696. https://doi.org/10.1002/cncr.30375
|
[21]
|
Verma, V., McMillan, M.T., Grover, S. and Simone, C.B. (2017) Stereotactic Body Radiation Therapy and the Influence of Chemotherapy on Overall Survival for Large (≥5 Centimeter) Non-Small Cell Lung Cancer. International Journal of Radiation Oncology∙Biology∙Physics, 97, 146-154. https://doi.org/10.1016/j.ijrobp.2016.09.036
|
[22]
|
Fujimoto, D., Uehara, K., Sato, Y., Sakanoue, I., Ito, M., Teraoka, S., et al. (2017) Alteration of PD-L1 Expression and Its Prognostic Impact after Concurrent Chemoradiation Therapy in Non-Small Cell Lung Cancer Patients. Scientific Reports, 7, Article No. 11373. https://doi.org/10.1038/s41598-017-11949-9
|
[23]
|
Badiyan, S.N., Roach, M.C., Chuong, M.D., Rice, S.R., Onyeuku, N.E., Remick, J., et al. (2018) Combining Immunotherapy with Radiation Therapy in Thoracic Oncology. Journal of Thoracic Disease, 10, S2492-S2507. https://doi.org/10.21037/jtd.2018.05.73
|
[24]
|
Simone II, C.B., Berman, A.T. and Jabbour, S.K. (2017) Harnessing the Potential Synergy of Combining Radiation Therapy and Immunotherapy for Thoracic Malignancies. Translational Lung Cancer Research, 6, 109-112. https://doi.org/10.21037/tlcr.2017.04.05
|
[25]
|
Jabbour, S.K., Berman, A.T. and Simone II, C.B. (2007) Integrating Immunotherapy into Chemoradiation Regimens for Medically Inoperable Locally Advanced Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 6, 113-118. https://doi.org/10.21037/tlcr.2017.04.02
|
[26]
|
Gray, J.E., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., et al. (2020) Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. Journal of Thoracic Oncology, 15, 288-293. https://doi.org/10.1016/j.jtho.2019.10.002
|
[27]
|
Shaverdian, N., Lisberg, A.E., Bornazyan, K., Veruttipong, D., Goldman, J.W., Formenti, S.C., et al. (2017) Previous Radiotherapy and the Clinical Activity and Toxicity of Pembrolizumab in the Treatment of Non-Small-Cell Lung Cancer: A Secondary Analysis of the KEYNOTE-001 Phase 1 Trial. The Lancet Oncology, 18, 895-903. https://doi.org/10.1016/s1470-2045(17)30380-7
|
[28]
|
Mok, T.S.K., Wu, Y., Kudaba, I., Kowalski, D.M., Cho, B.C., Turna, H.Z., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. https://doi.org/10.1016/s0140-6736(18)32409-7
|
[29]
|
Mittal, D., Gubin, M.M., Schreiber, R.D. and Smyth, M.J. (2014) New Insights into Cancer Immunoediting and Its Three Component Phases—Elimination, Equilibrium and Escape. Current Opinion in Immunology, 27, 16-25. https://doi.org/10.1016/j.coi.2014.01.004
|
[30]
|
Pardoll, D.M. (2012) Immunology Beats Cancer: A Blueprint for Successful Translation. Nature Immunology, 13, 1129-1132. https://doi.org/10.1038/ni.2392
|
[31]
|
Rizzo, A. and Ricci, A.D. (2022) PD-L1, TMB, and Other Potential Predictors of Response to Immunotherapy for Hepatocellular Carcinoma: How Can They Assist Drug Clinical Trials? Expert Opinion on Investigational Drugs, 31, 415-423. https://doi.org/10.1080/13543784.2021.1972969
|
[32]
|
Brody, R., Zhang, Y., Ballas, M., Siddiqui, M.K., Gupta, P., Barker, C., et al. (2017) PD-L1 Expression in Advanced NSCLC: Insights into Risk Stratification and Treatment Selection from a Systematic Literature Review. Lung Cancer, 112, 200-215. https://doi.org/10.1016/j.lungcan.2017.08.005
|
[33]
|
Zaric, B., Brcic, L., Buder, A., Brandstetter, A., Buresch, J.O., Traint, S., et al. (2018) PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma. Clinical Lung Cancer, 19, e957-e963. https://doi.org/10.1016/j.cllc.2018.08.014
|
[34]
|
Yu, H., Chen, Z., Ballman, K.V., Watson, M.A., Govindan, R., Lanc, I., et al. (2019) Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. Journal of Thoracic Oncology, 14, 25-36. https://doi.org/10.1016/j.jtho.2018.09.006
|
[35]
|
Tsao, M.-S., Le Teuff, G., Shepherd, F.A., Landais, C., Hainaut, P., Filipits, M., et al. (2017) PD-L1 Protein Expression Assessed by Immunohistochemistry Is Neither Prognostic Nor Predictive of Benefit from Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer. Annals of Oncology, 28, 882-889. https://doi.org/10.1093/annonc/mdx003
|
[36]
|
Chalmers, Z.R., Connelly, C.F., Fabrizio, D., Gay, L., Ali, S.M., Ennis, R., et al. (2017) Analysis of 100,000 Human Cancer Genomes Reveals the Landscape of Tumor Mutational Burden. Genome Medicine, 9, Article No. 34. https://doi.org/10.1186/s13073-017-0424-2
|
[37]
|
Owada-Ozaki, Y., Muto, S., Takagi, H., Inoue, T., Watanabe, Y., Fukuhara, M., et al. (2018) Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report. Journal of Thoracic Oncology, 13, 1217-1221. https://doi.org/10.1016/j.jtho.2018.04.003
|
[38]
|
Gandara, D.R., Paul, S.M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., et al. (2018) Blood-Based Tumor Mutational Burden as a Predictor of Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Atezolizumab. Nature Medicine, 24, 1441-1448. https://doi.org/10.1038/s41591-018-0134-3
|
[39]
|
Yarchoan, M., Hopkins, A. and Jaffee, E.M. (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. The New England Journal of Medicine, 377, 2500-2501. https://doi.org/10.1056/NEJMc1713444
|
[40]
|
Ettinger, D.S., Wood, D.E., Aggarwal, C., et al. (2019) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network, 17, 1464-1472. https://doi.org/10.6004/jnccn.2019.0059
|
[41]
|
Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. (2015) Cancer Immunology. Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer. Science, 348, 124-128. https://doi.org/10.1126/science.aaa1348
|
[42]
|
Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., et al. (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. New England Journal of Medicine, 376, 2415-2426. https://doi.org/10.1056/nejmoa1613493
|
[43]
|
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., et al. (2018) Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients with Non-Small-Cell Lung Cancer Profiled with Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 36, 633-641. https://doi.org/10.1200/JCO.2017.75.3384
|
[44]
|
Li, T., Zhao, L., Yang, Y., Wang, Y., Zhang, Y., Guo, J., et al. (2021) T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes. Cancer Research, 81, 2184-2194. https://doi.org/10.1158/0008-5472.can-20-2300
|
[45]
|
Farhood, B., Najafi, M. and Mortezaee, K. (2019) CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy: A Review. Journal of Cellular Physiology, 234, 8509-8521. https://doi.org/10.1002/jcp.27782
|
[46]
|
Liu, H., Zhang, T., Ye, J., Li, H., Huang, J., Li, X., et al. (2012) Tumor-Infiltrating Lymphocytes Predict Response to Chemotherapy in Patients with Advance Non-Small Cell Lung Cancer. Cancer Immunology, Immunotherapy, 61, 1849-1856. https://doi.org/10.1007/s00262-012-1231-7
|
[47]
|
Masucci, G.V., Cesano, A., Hawtin, R., Janetzki, S., Zhang, J., Kirsch, I., et al. (2016) Validation of Biomarkers to Predict Response to Immunotherapy in Cancer: Volume I—Pre-Analytical and Analytical Validation. Journal for ImmunoTherapy of Cancer, 4, Article 76. https://doi.org/10.1186/s40425-016-0178-1
|
[48]
|
(2018) High TMB Predicts Immunotherapy Benefit. Cancer Discovery, 8, Article 668. https://doi.org/10.1158/2159-8290.CD-NB2018-048
|
[49]
|
Samstein, R.M., Lee, C., Shoushtari, A.N., Hellmann, M.D., Shen, R., Janjigian, Y.Y., et al. (2019) Tumor Mutational Load Predicts Survival after Immunotherapy across Multiple Cancer Types. Nature Genetics, 51, 202-206. https://doi.org/10.1038/s41588-018-0312-8
|
[50]
|
Demaria, S., Kawashima, N., Yang, A.M., Devitt, M.L., Babb, J.S., Allison, J.P., et al. (2005) Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer. Clinical Cancer Research, 11, 728-734. https://doi.org/10.1158/1078-0432.728.11.2
|
[51]
|
Chakravarty, P.K., Alfieri, A., Thomas, E.K., et al. (1999) Flt3-Ligand Administration after Radiation Therapy Prolongs Survival in a Murine Model of Metastatic Lung Cancer. Cancer Research, 59, 6028-6032.
|
[52]
|
Nikitina, E.Y. and Gabrilovich, D.I. (2001) Combination of Gamma-Irradiation and Dendritic Cell Administration Induces a Potent Antitumor Response in Tumor-Bearing Mice: Approach to Treatment of Advanced Stage Cancer. International Journal of Cancer, 94, 825-833. https://doi.org/10.1002/1097-0215(20011215)94:6<825::AID-IJC1545>3.0.CO;2-5
|
[53]
|
Young, K.H., Baird, J.R., Savage, T., Cottam, B., Friedman, D., Bambina, S., et al. (2016) Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLOS ONE, 11, e0157164. https://doi.org/10.1371/journal.pone.0157164
|
[54]
|
Ko, E.C., Raben, D. and Formenti, S.C. (2018) The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. Clinical Cancer Research, 24, 5792-5806. https://doi.org/10.1158/1078-0432.ccr-17-3620
|
[55]
|
Levy, A., Massard, C., Soria, J.-C. and Deutsch, E. (2016) Concurrent Irradiation with the Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Blocker Durvalumab: Single Centre Subset Analysis from a Phase 1/2 Trial. European Journal of Cancer, 68, 156-162. https://doi.org/10.1016/j.ejca.2016.09.013
|
[56]
|
Hwang, W.L., Niemierko, A., Hwang, K.L., Hubbeling, H., Schapira, E., Gainor, J.F., et al. (2018) Clinical Outcomes in Patients with Metastatic Lung Cancer Treated with PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy. JAMA Oncology, 4, 253-255. https://doi.org/10.1001/jamaoncol.2017.3808
|
[57]
|
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., et al. (2021) DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-Tumor Immunity. Cancer Cell, 39, 96-108.e6. https://doi.org/10.1016/j.ccell.2020.11.006
|
[58]
|
Motz, G.T. and Coukos, G. (2013) Deciphering and Reversing Tumor Immune Suppression. Immunity, 39, 61-73. https://doi.org/10.1016/j.immuni.2013.07.005
|
[59]
|
Mole, R.H. (1953) Whole Body Irradiation; Radiobiology or Medicine? British Journal of Radiology, 26, 234-241. https://doi.org/10.1259/0007-1285-26-305-234
|
[60]
|
Sharabi, A.B., Lim, M., DeWeese, T.L. and Drake, C.G. (2015) Radiation and Checkpoint Blockade Immunotherapy: Radiosensitisation and Potential Mechanisms of Synergy. The Lancet Oncology, 16, e498-e509. https://doi.org/10.1016/S1470-2045(15)00007-8
|
[61]
|
McLaughlin, M., Patin, E.C., Pedersen, M., Wilkins, A., Dillon, M.T., Melcher, A.A., et al. (2020) Inflammatory Microenvironment Remodelling by Tumour Cells after Radiotherapy. Nature Reviews Cancer, 20, 203-217. https://doi.org/10.1038/s41568-020-0246-1
|